Announcements Trials

Browse Landscape

Phase

Status

Suspended 2 Unknown 1 Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2 Gynecologic 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

pembrolizumab 58 Cyclophosphamide 53 Ipilimumab 52 Nivolumab 44 aldesleukin 35 Interleukin-2 26 fludarabine phosphate 22 fludarabine 21 Vemurafenib 20 Temozolomide 19 Radiotherapy 18 dabrafenib 15 trametinib 12 Radiosurgery 11 CTLA-4 Antigen 11 Filgrastim 10 Dacarbazine 10 spartalizumab 9 cobimetinib 9 binimetinib 9 atezolizumab 9 Biopsy 9 poly ICLC 8 Paclitaxel 8 Antilymphocyte Serum 8 encorafenib 7 avelumab 7 Rituximab 7 Introns 7 romidepsin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Propranolol × Dermatologic × Clear all

NCT01705392 2017-02-24

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Haukeland University Hospital

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡